A study for a 68 year old woman who takes Hydroxychloroquine Sulfate, Pregabalin, Sulfasalazine, Co-Codamol - from FDA reports


Summary

73 females aged 68 (±5) who take the same drugs are studied. This is a personalized study for a 68 year old female patient who has Ra. The study is created by eHealthMe based on reports from FDA.

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA since 1977. Our tools are simple to use, anonymous and free. Start now >>>


On Sep, 11, 2017

73 females aged 68 (±5) who take Hydroxychloroquine Sulfate, Pregabalin, Sulfasalazine, Co-Codamol are studied.


Number of reports submitted per year:

Hydroxychloroquine Sulfate, Pregabalin, Sulfasalazine, Co-Codamol for a 68-year old woman.

Information of the patient in this study:

  • Age: 68
  • Gender: female
  • Conditions: Ra
  • Drugs taken:
    • Hydroxychloroquine Sulfate (hydroxychloroquine sulfate)
    • Pregabalin (pregabalin)
    • Sulfasalazine (sulfasalazine)
    • Co-Codamol (acetaminophen; codeine phosphate)

eHealthMe real world results:

Comparison with this patient's adverse outcomes:

  • Joint Aches: 0 (0% of females aged 68 (±5) who take the drugs)

As an adverse outcome could be a symptom of a condition, additional studies are listed to help identify the cause: for example, regardless of which drug is taken, how many female HBP patients aged 50 (±5) have nausea

As an adverse outcome could be a side effect of a drug, additional studies are listed to help identify the cause: for example, how many female Aspirin users aged 50 (±5) have nausea

Most common drug interactions over time

< 1 month:
  • lung infection
  • itching
  • diffuse interstitial lung disease
1 - 6 months:
  • poor venous access
  • pain in extremity
  • general physical health deterioration
  • osteopenia
  • osteoarthritis
  • neuropathy peripheral
  • drug ineffective
  • spinal column stenosis
  • carpal tunnel syndrome
  • hepatic enzyme increased
6 - 12 months:
  • arthropathy
  • drug ineffective
1 - 2 years:
  • neuropathy peripheral
  • osteopenia
  • osteoarthritis
  • drug ineffective
  • spinal column stenosis
  • carpal tunnel syndrome
  • blood pressure management
  • general physical health deterioration
  • treatment failure
  • hepatic enzyme increased
2 - 5 years:
  • carpal tunnel syndrome
  • drug ineffective
  • osteopenia
  • neuropathy peripheral
  • osteoarthritis
  • spinal column stenosis
  • itching
  • pain in extremity
  • lung infection
  • poor venous access
5 - 10 years:
n/a
10+ years:
n/a
not specified:
  • drug intolerance
  • psoriatic arthropathy
  • sinusitis
  • rashes
  • treatment failure
  • drug hypersensitivity
  • joint swelling
  • sciatica
  • diarrhea
  • osteoarthritis

Top conditions involved for these people *:

  • Dizziness (9 people, 12.33%)
  • Spinal Osteoarthritis (5 people, 6.85%)
  • Type 2 Diabetes (4 people, 5.48%)
  • Sleep Disorder (4 people, 5.48%)
  • Gastroesophageal Reflux Disease (4 people, 5.48%)

Top co-used drugs for these people *:

  • Enbrel (54 people, 73.97%)
  • Arava (47 people, 64.38%)
  • Rituxan (42 people, 57.53%)
  • Actemra (42 people, 57.53%)
  • Humira (40 people, 54.79%)

* Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Subscribe to the study: get notified of updates to the study.

You can also:

Expand the study to include reports from both FDA and eHealthMe

Expand this study to include FDA and eHealthMe reports

What are the drugs?

What are the conditions?

What are the symtoms?

Could your drugs cause:

Could your conditions cause:

Related studies:

Can you answer these questions?

More questions for: Sulfasalazine, Joint aches, Co-codamol, Ra, Hydroxychloroquine sulfate, Pregabalin

You may be interested in these reviews

More reviews for: Sulfasalazine, Joint aches, Co-codamol, Ra, Hydroxychloroquine sulfate, Pregabalin